Halozyme Therapeutics (HALO)
(Delayed Data from NSDQ)
$59.02 USD
-0.95 (-1.58%)
Updated Aug 1, 2025 04:00 PM ET
After-Market: $59.00 -0.02 (-0.03%) 7:58 PM ET
3-Hold of 5 3
B Value A Growth D Momentum A VGM
Fundamental Charts
About Cash from Investing (Quarterly)
The company's quarterly Cash from Investing value is the sum of the company's current quarter cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
HALO 59.02 -0.95(-1.58%)
Will HALO be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for HALO based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for HALO
Arcutis Biotherapeutics, Inc. (ARQT) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
Halozyme Therapeutics (HALO) Earnings Expected to Grow: Should You Buy?
HALO: What are Zacks experts saying now?
Zacks Private Portfolio Services
Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick
Why Halozyme Therapeutics (HALO) is Poised to Beat Earnings Estimates Again
Here's Why Halozyme Therapeutics (HALO) is a Strong Growth Stock
Other News for HALO
Fidelity Small Cap Index Fund Q2 2025 Commentary
Fidelity Small Cap Growth Fund Q2 2025 Commentary
J&J says Darzalex injectable granted EU nod for smouldering multiple myeloma
Halozyme says EU approves new indication for Janssen's Darzalex Faspro